Literature DB >> 31949706

Potential role of HGF-PARP-1 signaling in invasion of ovarian cancer cells.

Wei Wei1, Shuqing Lv1, Cancan Zhang1, Yongjie Tian1.   

Abstract

We investigated the effects and signaling pathways involved in both HGF-mediated regulation of PARP-1 expression and the invasion ability of ovarian cancer cells. Using a transwell assay, the invasiveness of SKOV-3 cells was tested by incubating them with increasing concentrations of HGF. The relative expression levels of PARP-1 after HGF treatment were analyzed by Real-Time PCR and western blotting. SKOV3 cells were transfected with either negative control siRNA or PARP-1 siRNA, and were divided into different groups as follows: control group; HGF group; PARP-siRNA group; HGF+PARP-siRNA group; NC-siRNA group; and HGF+NC-siRNA group. Western blotting was employed to measure the expression of PARP-1 in the different groups. Transwell tests were used to examine invasiveness. ELISA was applied to measure MMP-2 expression. HGF promotes cell invasion in a concentration- and time-dependent manner in SKOV-3 cells. The expression levels of PARP-1 increased after administration of 40 ng/ml HGF for 24 h. The expression of PARP-1 in the PARP1-siRNA group was lower compared with that in the NC-siRNA group (P < 0.05); PARP1-siRNA transfection significantly reduced the impact of HGF on invasiveness and MMP-2 expression in SKOV-3 cells. HGF promotes the invasiveness and metastasis of ovarian cancer cells. This effect could be related to the induction of increased expression levels of MMP-2 mediated by PARP-1. IJCEP
Copyright © 2018.

Entities:  

Keywords:  Hepatocyte growth factor (HGF); invasion; ovarian cancer; poly (ADP-ribose) polymerase-1

Year:  2018        PMID: 31949706      PMCID: PMC6962858     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  19 in total

1.  Lymph node metastasis of gastric cancer is associated with the interaction between poly (ADP-ribose) polymerase 1 and matrix metallopeptidase 2.

Authors:  JiHye Kim; Jung-A Pyun; Sung Won Cho; KwangJae Lee; KyuBum Kwack
Journal:  DNA Cell Biol       Date:  2011-05-25       Impact factor: 3.311

2.  Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells.

Authors:  Chao-Ming Hung; Daih-Huang Kuo; Chun-Hung Chou; Yen-Chao Su; Chi-Tang Ho; Tzong-Der Way
Journal:  J Agric Food Chem       Date:  2011-08-08       Impact factor: 5.279

3.  Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.

Authors:  Tomoyuki Nagai; Tokuzo Arao; Kazuyuki Furuta; Kazuko Sakai; Kanae Kudo; Hiroyasu Kaneda; Daisuke Tamura; Keiichi Aomatsu; Hideharu Kimura; Yoshihiko Fujita; Kazuko Matsumoto; Nagahiro Saijo; Masatoshi Kudo; Kazuto Nishio
Journal:  Mol Cancer Ther       Date:  2011-01       Impact factor: 6.261

4.  Epithelial ovarian cancer: An overview.

Authors:  Arpita Desai; Jingyao Xu; Kartik Aysola; Yunlong Qin; Chika Okoli; Ravipati Hariprasad; Ugorji Chinemerem; Candace Gates; Avinash Reddy; Omar Danner; Geary Franklin; Anachebe Ngozi; Guilherme Cantuaria; Karan Singh; William Grizzle; Charles Landen; Edward E Partridge; Valerie Montgomery Rice; E Shyam P Reddy; Veena N Rao
Journal:  World J Transl Med       Date:  2014-04-12

5.  Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells.

Authors:  Chie Kudo-Saito; Hiromi Shirako; Tadashi Takeuchi; Yutaka Kawakami
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

6.  Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression.

Authors:  Rosa Quiles-Perez; José Antonio Muñoz-Gámez; Angeles Ruiz-Extremera; Francisco O'Valle; Laura Sanjuán-Nuñez; Ana Belén Martín-Alvarez; David Martín-Oliva; Trinidad Caballero; Paloma Muñoz de Rueda; Josefa León; Raúl Gonzalez; Jordi Muntané; Francisco Javier Oliver; Javier Salmerón
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

Review 7.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

8.  HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer.

Authors:  Marisa Mariani; Mark McHugh; Marco Petrillo; Steven Sieber; Shiquan He; Mirko Andreoli; Zheyang Wu; Paul Fiedler; Giovanni Scambia; Shohreh Shahabi; Cristiano Ferlini
Journal:  Oncotarget       Date:  2014-07-15

9.  Catalpol suppresses proliferation and facilitates apoptosis of OVCAR-3 ovarian cancer cells through upregulating microRNA-200 and downregulating MMP-2 expression.

Authors:  Na Gao; Jian-Xin Tian; Yu-Hong Shang; Dan-Yi Zhao; Tao Wu
Journal:  Int J Mol Sci       Date:  2014-10-24       Impact factor: 5.923

10.  Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance & proliferation of the ovarian cancer C13* cells.

Authors:  Jingjing Zhang; Yanyan Kan; Yongjie Tian; Zhe Wang; Jie Zhang
Journal:  Indian J Med Res       Date:  2013-03       Impact factor: 2.375

View more
  3 in total

Review 1.  The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions.

Authors:  Máté A Demény; László Virág
Journal:  Cancers (Basel)       Date:  2021-04-24       Impact factor: 6.639

2.  Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden.

Authors:  Annie Ren; Ioannis Prassas; Vijithan Sugumar; Antoninus Soosaipillai; Marcus Bernardini; Eleftherios P Diamandis; Vathany Kulasingam
Journal:  F1000Res       Date:  2021-06-28

3.  Bacterial, Archaea, and Viral Transcripts (BAVT) Expression in Gynecological Cancers and Correlation with Regulatory Regions of the Genome.

Authors:  Jesus Gonzalez-Bosquet; Silvana Pedra-Nobre; Eric J Devor; Kristina W Thiel; Michael J Goodheart; David P Bender; Kimberly K Leslie
Journal:  Cancers (Basel)       Date:  2021-03-05       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.